SEC Tracker
Get the app

Integra Lifesciences Holdings IART

Integra Lifesciences Holdings FY 2020: revenue $1.4B; diluted EPS $1.57

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Integra Lifesciences Holdings reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.4BNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income$133.9MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS$1.57No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$470.2MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  5. Cash from operations$203.8MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Integra Lifesciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Establishment Labs Holdings ESTA public float $975M, Jun 30, 2025
  2. NovoCure NVCR public float $995M, Jun 30, 2025
  3. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  4. SI-BONE SIBN public float $800M, Jun 30, 2025
  5. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.